AstraZeneca recently announced that its bronchodilator inhalation aerosol medicine Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), namely, patients suffering from chronic bronchitis and/or emphysema. Bevespi Aerosphere is the…
Sunovion Pharmaceuticals, Inc., recently reported positive data on its Phase 3 clinical development program for SUN-101 (glycopyrrolate) for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). SUN-101 is dispensed using PARI’s investigational and proprietary nebulizer system, called eFlow. Two 12-week, randomized, double-blind, placebo-controlled and parallel-group, Phase 3 efficacy and safety trials (GOLDEN-3 and…
In the first large-scale study comparing the transcriptomics of a variety of lung diseases, Yale scientists revealed that chronic obstructive pulmonary disease (COPD) shares a network of underlying genes with idiopathic pulmonary fibrosis – another devastating lung disease. The new findings advance our understanding of both conditions, and might possibly…
Researchers at the University of Granada (UGR) and Virgen de las Nieves Hospital in Spain revealed that a brief exercise program, from 7 to 10 days, can improve quality of life and physical abilities while minimizing the need for hospitalization in patients with chronic obstructive pulmonary disease (COPD). The research article, “Results…
Aptar Pharma, a global provider of aerosols for healthcare and pharma products, unveiled its latest innovation — the eDose Counter for metered dose inhalers (MDIs) — at the Respiratory Drug Delivery (RDD) Scientific Conference April 17-21 in Phoenix, Arizona. The eDose Counters are engineered to improve treatment adherence in patients…
Propeller Health and AMC Health are partnering to assist patients with chronic obstructive pulmonary disease (COPD) and asthma manage their disease more efficiently and reduce symptoms, as well as hospital visits. The multi-year partnership was signed in January and will kick off this month with the launch of two…
A collaborative research study between several Australian institutions suggests that cigarette smoking and infection with viruses such as influenza can reduce the effectiveness of symptom-reliever drugs like salbutamol in patients with chronic obstructive pulmonary disease (COPD). These findings were published in a research article, “Influenza A virus…
Boehringer Ingelheim recently announced the publication of a new research article detailing the measurement of specific white blood cells, called eosinophils, to prediction the response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. The study was developed using data from the…
A research team discovered that innate lymphoid cells need certain nutrients to function, a finding that may lead to new treatments for patients with chronic obstructive pulmonary disease (COPD) and other inflammatory lung disorders. Researchers have long known that innate lymphoid cells play a vital role in promoting inflammatory reactions in the…
The U.S. Food and Drug Administration (FDA) recently approved a Supplemental New Drug Application (sNDA) for Boehringer Ingelheim Pharmaceuticals Inc.‘s Stiolto Respimat, adding data to the product’s labeling to reflect its demonstrated capacity to improve health-related quality of life in people with chronic obstructive pulmonary disease (COPD). Data came from Phase 3 clinical trials, OTEMTO…
Get regular updates to your inbox.